| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer | Director
2 companies
Sandip Kapadia is Chief Financial Officer at HRMY and has filed Form 4s across 2 companies. Sandip Kapadia's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $908K at current prices.
Historically, Sandip Kapadia's trades have earned a strong insider score of 71/100 across 9 rated trades. Over a 12-month horizon, 80.0% of those trades were profitable, with an average 12-month return of +13.0%.
The biggest single holding is HRMY (~$908K) as Chief Financial Officer. The HRMY filings lean toward selling, a net 103,469 shares.
Sandip Kapadia has 26 Form 4 filings on record from February 2020 to May 2026, across 2 companies: Director at Passage Bio (PASG), 2020–2026; Chief Financial Officer at Harmony Biosciences (HRMY), 2021–2026.
The 45 reported transactions were 16 option or other derivative awards, 10 open-market sales, 10 option exercises and 8 tax withholdings, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $90K and 9 sales worth about $3.9M.
The only open-market purchase was 5,000 shares of PASG at an average $18.00 on March 3, 2020, about $90K.
The largest open-market sale was 25,000 shares of HRMY at an average $40.18 on January 21, 2025, about $1.0M. Twelve months later HRMY was down 9%.
All 8 sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 26, 2026 | HRMY Harmony Biosciences Holdings, Inc. | Chief Financial Officer | Sell10b5-1 | 3,746 | $37.15 | $139,171.39 | -13.3% | -16.9% | - | |
| Jan 15, 2026 | HRMY Harmony Biosciences Holdings, Inc. | Chief Financial Officer | Sell10b5-1 | 20,961 | $35.92 | $752,833.18 | -100% | -19.7% | - | |
| Dec 5, 2025 | HRMY Harmony Biosciences Holdings, Inc. | Chief Financial Officer | Sale+OE10b5-1 | 20,000 | $39.54 | $790,896.00 | - | -28.4% | - | |
| Nov 21, 2025 | HRMY Harmony Biosciences Holdings, Inc. | Chief Financial Officer | Sell10b5-1 | 3,427 | $35.00 | $119,945.00 | -100% | +0.2% | - | |
| Aug 15, 2025 | HRMY Harmony Biosciences Holdings, Inc. | Chief Financial Officer | Sell10b5-1 | 21,573 | $36.50 | $787,377.83 | -100% | -7.0% | +3.4% | |
| Apr 1, 2025 | HRMY Harmony Biosciences Holdings, Inc. | Chief Financial Officer | Sell10b5-1 | 6,987 | $32.54 | $227,385.94 | -100% | -2.5% | -13.8% | |
| Jan 27, 2025 | HRMY Harmony Biosciences Holdings, Inc. | Chief Financial Officer | Sale+OE10b5-1 | 1,775 | $38.05 | $67,547.27 | - | -23.2% | -1.5% | |
| Jan 21, 2025 | HRMY Harmony Biosciences Holdings, Inc. | Chief Financial Officer | Sale+OE10b5-1 | 25,000 | $40.18 | $1,004,597.50 | - | -29.6% | -9.3% | |
| Dec 1, 2022 | PASG Passage Bio, Inc. | Director | Sell | 5,000 | $1.19 | $5,964.50 | -100% | +8.4% | -43.9% | |
| Mar 3, 2020 | PASG Passage Bio, Inc. | Director | Buy | 5,000 | $18.00 | $90,000.00 | New | - | - |